610 related articles for article (PubMed ID: 27059853)
1. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
2. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
[TBL] [Abstract][Full Text] [Related]
5. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
6. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study.
Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC
Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624
[TBL] [Abstract][Full Text] [Related]
7. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma.
Janssen I; Chen CC; Millo CM; Ling A; Taieb D; Lin FI; Adams KT; Wolf KI; Herscovitch P; Fojo AT; Buchmann I; Kebebew E; Pacak K
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1784-91. PubMed ID: 26996779
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
11. Superiority of
Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
[TBL] [Abstract][Full Text] [Related]
12. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer.
Vrachimis A; Burg MC; Wenning C; Allkemper T; Weckesser M; Schäfers M; Stegger L
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):212-220. PubMed ID: 26419851
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.
Kundu P; Lata S; Sharma P; Singh H; Malhotra A; Bal C
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1354-62. PubMed ID: 24562651
[TBL] [Abstract][Full Text] [Related]
14. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
Hempel JM; Kloeckner R; Krick S; Pinto Dos Santos D; Schadmand-Fischer S; Boeßert P; Bisdas S; Weber MM; Fottner C; Musholt TJ; Schreckenberger M; Miederer M
Cancer Imaging; 2016 Nov; 16(1):37. PubMed ID: 27809936
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of [
Ballal S; Yadav MP; Roesch F; Satapathy S; Moon ES; Martin M; Wakade N; Sheokand P; Tripathi M; Chandekar KR; Agarwal S; Sahoo RK; Rastogi S; Bal C
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):233-244. PubMed ID: 37642703
[TBL] [Abstract][Full Text] [Related]
17. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data.
Middendorp M; Selkinski I; Happel C; Kranert WT; Grünwald F
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):76-83. PubMed ID: 20168289
[TBL] [Abstract][Full Text] [Related]
18. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
[TBL] [Abstract][Full Text] [Related]
19. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]